Shavit Capital

Shavit Capital is a private equity firm specializing in late-stage investments in Israeli and Israeli-related companies. Founded in 2008, the firm manages over $500 million across five separate funds, focusing on companies with proven technologies, products, markets, and strong management teams. Shavit Capital primarily invests in equity mezzanine or bridge rounds for companies planning IPOs on major international exchanges or dual listings on the Tel Aviv Stock Exchange. The firm also engages in other late-stage opportunities, including Private Investments in Public Equity (PIPEs) of publicly traded companies.

The firm's investment strategy emphasizes flexibility, timeliness, and cost-effectiveness, aiming to support companies in their pursuit of IPOs and other exit strategies. Shavit Capital works closely with leading international investment banks and underwriters to obtain direct feedback on the viability and best approach for an IPO, PIPE, or dual listing. The firm leads investment rounds ranging from $20 million to $60 million, with co-investors including leading financial institutions from the United States, Asia, and Israel. Shavit Capital grants confidence in existing management teams, enabling companies to pursue their goals and strategies with minimal intervention.

Shavit Capital's portfolio includes notable companies such as Foamix Pharmaceuticals, Kamada, Anchiano Tx (formerly BioCancell), Gamida Cell, Brainsway, Alpha TAU Medical, and PolyPid. The firm has a strong track record of supporting companies through successful IPOs and other exit strategies, contributing to the growth and success of its portfolio companies in various sectors, including technology, life sciences, healthcare, fintech, cybersecurity, artificial intelligence, semiconductors, data storage, digital media, enterprise software, cloud computing, DevOps, enterprise infrastructure, quantum computing, and infrastructure.